Rapid learning for precision oncology

Nature Reviews Clinical Oncology

Volumn 11, Issue 2, 2014, Pages 109-118

  Shrager, Jeff ^a   Tenenbaum, Jay M ^b  

^a CommerceNet ^*  (United States)

^b Cancer Commons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; HUMANS; MEDICAL INFORMATICS; MEDICAL ONCOLOGY; NEOPLASMS; PHARMACOGENETICS; SIGNAL TRANSDUCTION;

EID: 84895900452     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.244     Document Type: Review

References (89)

1. Pleasance, E. D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
2. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
3. Blau, C. A. & Liakopoulou, E. Can we deconstruct cancer, one patient at a time Trends Genet. 29, 6-10 (2013).
4. Garraway, L. A. Genomics-driven oncology: Framework for an emerging paradigm. J. Clin. Oncol. 31, 1806-1814 (2013).
5. Roukos, D. H. Trastuzumab and beyond: Sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11, 81-92 (2011).
6. Vallat, L. et al. Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 110, 459-464 (2013).
7. Centre for Integrated Diagnostics. Massachusetts General Hospital [online], http://www.massgeneral.org/pathology/clinical/molecular.aspx (2013).
8. UW-OncoPlex-Cancer Gene Panel. University of Washington [online], http://web.labmed.washington.edu/tests/genetics/UW-OncoPlex (2013).
9. Foundation Medicine [online], http://www.foundationmedicine.com/(2013).
10. News. Caris life s ciences [online], http://www.carislifesciences.com/ news/caris-life-sciences-to-present-on-biomarker-expression-at-the-society-of- gynecologic-oncologists-2011-annual-meeting-on-womens-cancer/(2013).
11. BGI [online], http://www.genomics.cn/en/index (2013).
12. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
13. Lefebvre, C., Rieckhof, G. & Califano, A. Reverse-engineering human regulatory networks. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 311-325 (2012).
14. Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2013).
15. Schreiber, S. L. et al. Towards patient-based cancer therapeutics. Nat. Biotechnol. 28, 904-906 (2010).
16. Califano, A., Butte, A. J., Friend, S., Ideker, T. & Schadt, E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 44, 841-847 (2012).
17. Del Sol, A., Balling, R., Hood, L. & Galas, D. Diseases as network perturbations. Curr. Opin. Biotechnol. 21, 566-571 (2010).
18. Quayle, A. P., Siddiqui, A. S. & Jones, S. J. M. Perturbation of interaction networks for application to cancer therapy. Cancer Inform. 5, 45-65 (2007).
19. Macconaill, L. E. & Garraway, L. A. Clinical implications of the cancer genome. J. Clin. Oncol. 28, 5219-5228 (2010).
20. Bay, S. D., Shrager, J., Pohorille, A. & Langley, P. Revising regulatory networks: From expression data to linear causal models. J. Biomedical Informatics 35, 289-297 (2002).
21. Shrager, J., Langley, P. & Pohorille, A. Guiding revision of regulatory models with expr ession data. Pac. Symp. Biocomput. 7, 486-497 (2002).
22. D'haeseleer, P., Liang, S. & Somogyi, R. Genetic network inference: From coexpression clustering to reverse engineering. Bioinformatics 16, 707-726 (2000).
23. Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382-390 (2005).
24. Vaske, C. J. et al. Inf erence of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
25. Goutsias, J. & Lee, N. H. Computational and experimenta l approaches for modeling gene regulatory networks. Curr. Pharm. Des. 13, 1415-1436 (2007).
26. Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumour suppressor in T-ALL. Nat. Med. 18, 436-440 (2012).
27. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
28. Kaiser, J. Biomedicine. Rare cancer successes spawn 'exceptional' research efforts. Science 340, 263 (2013).
29. Ginsburg, G. S. & Kuderer, N. M. Comparative effectiveness research, ge nomics-enabled personalized medicine, and rapid learning health care: A common bond. J. Clin. Oncol. 30, 4233-4242 (2012).
30. Beltran, H. et al. A targeted next-generation sequencing of advanced prost ate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920-926 (2013).
31. Meric-Bernstam, F., Farhangfar, C., Mendelsohn, J. & Mills G. B. Building a personalized medicine infrastructure at a major cancer centre. J. Clin. Oncol. 31, 1849-1857 (2013).
32. Balbin, O. A. et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat. Commun. http://dx.doi:10.1038/ncomms3617 (2013).
33. Mount Sinai to Test. Cancer Network Mod eling Approach in Two Clinical Trials March 27, GenomeWeb [online], http://icahn.mssm.edu/static-files/MSSM/ Genomics/Clin.Seq-050913-2.pdf (2013).
34. GeneKey [online], http://www.genekey.com/.
35. Tailored clinical molecular test interpretation. N-of-One [online], http://www.n-of-one.com/.
36. Olsen, L. A., Aisner, D. & McGinnis, J. M. The Learning Healthcare System: Workshop summary (Inst itute Of Medicine roundtable on evidence-based medicine). The National Academies Press (2007).
37. Etheredge, L. M. A rapid-learning health system. Health Aff. 26, w107-w118 (2007).
38. Murphy, S. & Patlak, M. A foundation for evidence-driven practice: A rapid-learning system for cancer care: Workshop summary. The National Academies Press (2009).
39. Abernethy A. P. et al. Rapid-learning system for cancer care. J. Clin. Oncol. 28, 4268-4274 (2010).
40. Fenstermacher, D. A., Wenham, R. M., Rollison, D. E. & Dalton, W. S. Implementing personalized medicine in a cancer centre. Cancer J. 17, 528-536 (2011).
41. Ren, Y. et al. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci. Rep. 3, 3042 (2013).
42. Fox, E. J., Salk, J. J. & Loeb, L. A. Cancer genome sequencing: An interim analysis. Cancer Res. 69, 4948-4950 (2009).
43. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
44. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
45. Weinberg, R. A. The Biology of Cancer. (Garland Science, New York, 2007).
46. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
47. Pathways to Cancer. Inside Teacher Cancer Centre [online], http://teachercentre.insidecancer.org/browse/Pathways%20to%20Cancer/(2013).
48. Lamb, J. et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
49. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
50. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486, 346-352 (2012).
51. Lundberg, G. D. Medical Publishing for an N of One. The Scientist 25, 31 (2011).
52. National Research Council. Committee on a framework for development a new taxonomy of disease. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. The National Academies Press (2011).
53. PLoS Currents [online], http://currents.plos.org/(2013).
54. Ram, K. Git can facilitate greater reproducibility and increased transparency in science. Source Code Biol. Med. 8, 7 (2013).
55. Gallo, P. et al. Adaptive designs in clinical drug development-an executive summary of the PhRMA working group. J. Biopharm. Stat. 16, 275-283 (2006).
56. Fiore, L. D. et al. A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin. Trials 8, 183-195 (2011).
57. Kim, E. S. et al. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
58. Berry, D. A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2012).
59. D'Avolio, L. et al. Implementation of the Department of Veterans Affairs' first point-of-care clinical trial. J. Am. Med. Inform. Assoc. 19, e170-e176 (2012).
60. Scher, H. I., Nasso, S. F., Rubin, E. H. & Simon, R. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin. Cancer Res. 17, 6634-6640 (2011).
61. Shrager, J. Theoretical Issues for Global Cumulative Treatment Analysis (GCTA). Cornell University Library [online], http://arxiv.org/abs/1308.1066 (2013).
62. Vickers, A. J. & Scardino, P. T. The clinically-integrated randomized trial: Proposed novel method for conducting large trials at low cost. Trials 10, 14 (2009).
63. Huber, P. The digital future of molecular medicine: Rethinking FDA regulation. Project FDA report no. The Manhattan Institute [online] http://www.manhattan-institute.org/pdf/fda-06.pdf (2013).
64. Shrager, J. & Tenenbaum, J. M. Cancer Commons: Biomedicine in the internet age. In Collaborative Computational Technologies for Biomedical Research (ed. Elkin, S.) 161-177 (John Wiley & Sons, 2011).
65. Tenenbaum, J. M. & Shrager, J. Cancer: A computational disease that AI can cure. AI Magazine 32, 14-26 (2011).
66. Sledge, G. W. et al. ASCO's Approach to a Learning Health Care System in Oncology. J. Oncol. Pract. 9, 145-148 (2013).
67. ASCO's CancerLinQ: Building a Transformation in Cancer Care. ASCO [online] http://www.ascopost.com/issues/july-1-2012/asco%E2%80%99s-cancerlinq- building-a-transformation-in-cancer-care.aspx (2013).
68. ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a "Learnin g Health System" to Transform Cancer Care. ASCO [online], http://www.asco.org/press-centre/asco-completes-prototype- cancerlinq%E2%84%A2-marking-first-demonstration-%E2%80%9Clearning-health (2013).
69. Malin, J. L. Envisioning Watson as a rapid-learning system for oncology. J. Oncol. Pract. 9, 155-157 (2013).
70. IBM Watson helps fight cancer with evidence-based diagnosis and treatment suggestions. Memorial Sloan-Ketter ing Cancer Centre [online], http://www-03.ibm.com/innovation/us/watson/pdf/MSK-Case-Study-IMC14794.pdf (2013).
71. Vidwans, S. et al. A melanoma molecular disease model. PLoS ONE 6, e18257 (2011).
72. West, L. et al. A novel classification of lung cancer into molecular subtypes. PLoS ONE 7, e31906 (2012).
73. Participate in rapid learning communities. Cancer Commons [online], http://www.cancercommons.org/researchers-clinicians/(2013).
74. Donate Your Data. Cancer Commons [online], http://www.cancercommons.org/ donate-your-data/(2013).
75. Grove, A. Rethinking clinical trials. Science 23, 1679 (2011).
76. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01449279 (2013).
77. Wolchok, J. D. Emerging therapies in melanoma. Clin. Adv. Haematol. Oncol. 10, 742-743 (2012).
78. DNA Sequencing Costs. National Human Genome Research Institute [online], http://www.genome.gov/sequencingcosts/(2013).
79. Monks, N. R. et al. A multi-site feasibility study for personalized medicine in canines with Osteosarcoma. J. Transl. Med. 11, 158 (2013).
80. Hoepman, J. H. & Jacobs, B. Increased security through open source. Commun. ACM 50, 79-83 (2007).
81. Anderson, R. J. Open a nd closed source systems are equivalent (that is, in an ideal world). In Perspectives on free and open source software. 127-142 (The MIT Press, Cambridge, MA, 2005).
82. Shrager, J., Billman, D., Converti no, G., Massar, J. P. & Pirolli, P. Soccer science and the Bayes community: Exploring the cognitive implications of modern scientific communication. Top. Cog. Sci. 2, 53-72 (2009).
83. Domingos, P. & Webb, W. A. A tractable first-order probabilistic logic [abstract]. Proceedings of the 26th AAAI Conference on Artificial Intelligence. Toronto, Canada (2012).
84. Humphrey, R. W. et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl Cancer Inst. 103, 1222-1226 (2011).
85. Willyard, C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat. Med. 19, 655 (2013).
86. Lerose, R., Musto, P., Aieta, M., Papa, C. & Tartarone, A. Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience. Eur. J. Clin. Pharmacol. 68, 505-512 (2012).
87. McCabe, C. et al. Market and patient access to new oncology products in Europe: A current, multidisciplinary perspective. Ann. Oncol. 20, 403-412 (2009).
88. Doroshow, J. H. Personal communication to Jeff Shrager. 2013-08-14.
89. Cancer Research UK. Stratified Medicine Programme [online], http://www.cancerresearchuk.org/science/research/how-we-deliver-our-research/ others/by-programme/stratified-medicine-programme/(2013).